RBC Capital raised the firm’s price target on BioCryst (BCRX) to $13 from $11 and keeps an Outperform rating on the shares after its Q1 results. The company’s fundamentals continue to improve, with an Orladeyo beat/raise driven by more rapid paid drug conversion, debt payback on a faster schedule, and profitability now expected this year, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst price target raised to $13 from $11 at BofA
- BioCryst’s Strong Growth Prospects: Buy Rating Backed by Orladeyo’s Success and Promising Pipeline Developments
- BioCryst Pharmaceuticals Reports Strong Q1 2025 Growth
- BioCryst Pharmaceuticals Reports Record Growth and Profitability
- Strong Growth Prospects for BioCryst’s Orladeyo Drive Buy Rating and Increased Price Target